Results 301 to 310 of about 1,071,989 (385)

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Increased extracellular volume after aortic valve replacement: A footprint of reverse ventricular remodeling that does not affect conduction velocity. [PDF]

J Cardiovasc Magn Reson
Sobota V, Augustin CM, Plank G, Vigmond EJ, Nordmeyer S, Bayer JD.   +5 more
europepmc   +1 more source

EFFECTS OF ENDOVASCULAR INTERVENTION VS. THROMBOLYSIS ON INTRACARDIAC HEMODYNAMICS AND LEFT VENTRICULAR REMODELLING IN ACUTE MYOCARDIAL INFARCTION

, 2012
M. Kh. Makoeva, S.P. Semitko, А. Г. Автандилов   +2 more
openalex   +1 more source

Resveratrol Treatment Reduces Cardiac Progenitor Cell Dysfunction and Prevents Morpho-Functional Ventricular Remodeling in Type-1 Diabetic Rats

, 2012
Francesca Delucchi, Roberta Berni, Caterina Frati, Stefano Cavalli, Gallia Graiani, Roberto Sala, Christine Chaponnier, Giulio Gabbiani, Luca Calani, Daniele Del Rio, Leonardo Bocchi, Costanza Lagrasta, Federico Quaini, Donatella Stilli   +13 more
openalex   +2 more sources

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu, Gui‐Qin Liu, Ya‐Ping Peng, Li‐Ling Zhang, Xian‐Jin Wang, Liang‐Chuan Chen, Yuan‐Xi Zheng, Xue‐Jun Xiang, Rui Qiao, Xian‐He Lin   +9 more
wiley   +1 more source

Association between left ventricular remodeling and coronary chronic total occlusion in hypertensive coronary artery disease patients. [PDF]

Sci Rep
He W, Yao Q, Li D, Sui X, Zhang W.
europepmc   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Iron in ventricular remodeling and aneurysms post-myocardial infarction. [PDF]

Open Med (Wars)
Wang Z, Ding X, Pan J, Wang X, Lin J, Wang X.   +5 more
europepmc   +1 more source

CardiLect: A combined cross‐species lectin histochemistry protocol for the automated analysis of cardiac remodelling

ESC Heart Failure, Volume 12, Issue 2, Page 1398-1415, April 2025.
Abstract Background Cardiac remodelling, a crucial aspect of heart failure, is commonly investigated in preclinical models by quantifying cardiomyocyte cross‐sectional area (CSA) and microvascular density (MVD) via histological methods, such as immunohistochemistry.
Tamás G. Gergely, Tamás Kovács, Andrea Kovács, Viktória E. Tóth, Nabil V. Sayour, Gábor M. Mórotz, Csenger Kovácsházi, Gábor B. Brenner, Zsófia Onódi, Balázs Enyedi, Domokos Máthé, Przemyslaw Leszek, Zoltán Giricz, Péter Ferdinandy, Zoltán V. Varga   +14 more
wiley   +1 more source